Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927124 | 0.90 | RAB9A (0.46) | RAB9AKMT2ARORCALDH1A1LMNA | |
| SCHEMBL926278 | 0.88 | MMP8 (0.44) | RAB9AKMT2AMMP8ALDH1A1LMNA | |
| SCHEMBL4838970 | 0.86 | PPARD (0.39) | RORCKDM1AMMP8MMP3 | |
| SCHEMBL926562 | 0.83 | NPC1 (0.50) | RAB9AKMT2ARORCMMP8ALDH1A1 | |
| SCHEMBL4842553 | 0.82 | MMP8 (0.41) | RORCKDM1AMMP8MMP3 | |
| SCHEMBL925329 | 0.82 | EPHX2 (0.47) | RAB9AKMT2ARORCMMP8ALDH1A1 | |
| SCHEMBL926649 | 0.82 | MMP8 (0.44) | RAB9AKMT2ARORCMMP8ALDH1A1 | |
| SCHEMBL4844578 | 0.81 | RORC (0.35) | RORCMMP8ALDH1A1MMP3NPSR1 | |
| SCHEMBL4841159 | 0.81 | RORC (0.40) | RORCMMP8LMNAMMP3 | |
| SCHEMBL4845042 | 0.81 | PPARD (0.41) | KDM1AMMP8MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872021-B2 | LXR receptor modulators | LABORATORIES FOURNIER S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | RAB9A 3853/4885KMT2A 2387/4885RORC 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.